EA201401259A1 - Фторированные мостиковые производные спиро[2,4]гептана в качестве агонистов рецептора alx - Google Patents

Фторированные мостиковые производные спиро[2,4]гептана в качестве агонистов рецептора alx

Info

Publication number
EA201401259A1
EA201401259A1 EA201401259A EA201401259A EA201401259A1 EA 201401259 A1 EA201401259 A1 EA 201401259A1 EA 201401259 A EA201401259 A EA 201401259A EA 201401259 A EA201401259 A EA 201401259A EA 201401259 A1 EA201401259 A1 EA 201401259A1
Authority
EA
Eurasian Patent Office
Prior art keywords
spiro
fluorinated
derivatives
heptana
agonists
Prior art date
Application number
EA201401259A
Other languages
English (en)
Other versions
EA025264B1 (ru
Inventor
Оливье Корменбёф
Давиде Поцци
Original Assignee
Актелион Фармасьютиклз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Актелион Фармасьютиклз Лтд. filed Critical Актелион Фармасьютиклз Лтд.
Publication of EA201401259A1 publication Critical patent/EA201401259A1/ru
Publication of EA025264B1 publication Critical patent/EA025264B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Настоящее изобретение касается фторированных мостиковых производных спиро[2.4]гептана формулы (I)в которой n и Rявляются такими, как определено в описании, их получения и их применения в качестве фармацевтически активных соединений.
EA201401259A 2012-05-16 2013-05-15 Фторированные мостиковые производные спиро[2,4]гептана в качестве агонистов рецептора alx EA025264B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12168322 2012-05-16
PCT/IB2013/053976 WO2013171694A1 (en) 2012-05-16 2013-05-15 Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists

Publications (2)

Publication Number Publication Date
EA201401259A1 true EA201401259A1 (ru) 2015-04-30
EA025264B1 EA025264B1 (ru) 2016-12-30

Family

ID=48699893

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201401259A EA025264B1 (ru) 2012-05-16 2013-05-15 Фторированные мостиковые производные спиро[2,4]гептана в качестве агонистов рецептора alx

Country Status (23)

Country Link
US (1) US9139524B2 (ru)
EP (1) EP2850060B1 (ru)
JP (1) JP6101789B2 (ru)
KR (1) KR20150013285A (ru)
CN (1) CN104321309B (ru)
AR (1) AR091059A1 (ru)
AU (1) AU2013261091B2 (ru)
BR (1) BR112014028358A2 (ru)
CA (1) CA2871336A1 (ru)
CL (1) CL2014002918A1 (ru)
EA (1) EA025264B1 (ru)
ES (1) ES2595219T3 (ru)
HK (1) HK1208441A1 (ru)
IL (1) IL235660A0 (ru)
MA (1) MA37618B1 (ru)
MX (1) MX355221B (ru)
NZ (1) NZ702971A (ru)
PH (1) PH12014502465A1 (ru)
PL (1) PL2850060T3 (ru)
SG (1) SG11201406971WA (ru)
TW (1) TWI579269B (ru)
WO (1) WO2013171694A1 (ru)
ZA (1) ZA201409249B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2814826C (en) 2010-11-17 2019-02-12 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
KR101847672B1 (ko) 2010-12-07 2018-04-10 이도르시아 파마슈티컬스 리미티드 Alx 수용체 작용제로서의 히드록실화 아미노트리아졸 유도체
WO2013171687A1 (en) 2012-05-16 2013-11-21 Actelion Pharmaceuticals Ltd 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
ES2639798T3 (es) 2013-07-18 2017-10-30 Idorsia Pharmaceuticals Ltd Derivados de espiro[2.4]heptano con puente sustituidos con piperazina como agonistas del receptor ALX
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
MY186570A (en) 2014-05-13 2021-07-27 Novartis Ag Compounds and compositions for inducing chondrogenesis
US10525058B2 (en) 2015-05-27 2020-01-07 Kyorin Pharmaceutical Co., Ltd Urea derivative or pharmacologically acceptable salt thereof
US10858314B2 (en) 2015-05-27 2020-12-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
CN111233751B (zh) * 2020-03-25 2021-02-02 丽水绿氟科技有限公司 一种3,3-二氟-4-氨基哌啶类化合物及其衍生物的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09500133A (ja) * 1993-07-16 1997-01-07 メルク エンド カンパニー インコーポレーテッド オキシトシンのアンタゴニストである置換ピペラジニル樟脳誘導体
EP1492552A2 (en) 2002-04-03 2005-01-05 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
CN1863773A (zh) 2003-10-09 2006-11-15 埃科特莱茵药品有限公司 四氢吡啶衍生物
EP1692502A2 (en) 2003-11-07 2006-08-23 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
TW200538098A (en) 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
US7820699B2 (en) 2005-04-27 2010-10-26 Hoffmann-La Roche Inc. Cyclic amines
CN101679422A (zh) 2007-03-28 2010-03-24 阵列生物制药公司 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
DK2225231T3 (da) 2007-12-18 2011-10-17 Actelion Pharmaceuticals Ltd Aminotriazolderivater som alx-agonister
KR101724765B1 (ko) * 2009-05-18 2017-04-07 액테리온 파마슈티칼 리미티드 Ａｌｘ 수용체 및/또는 ｆｐｒｌ2 아고니스트로서의 브릿지 스피로［2.4］헵탄 유도체
JP5095035B2 (ja) 2009-06-09 2012-12-12 アクテリオン ファーマシューティカルズ リミテッド フッ素化アミノトリアゾール誘導体
US8674111B2 (en) 2009-06-12 2014-03-18 Actelion Pharmaceuticals Ltd. Oxazole and thiazole derivatives as ALX receptor agonists
CA2803920A1 (en) * 2010-06-24 2011-12-29 Richard Beard Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
CA2814826C (en) 2010-11-17 2019-02-12 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
KR101847672B1 (ko) 2010-12-07 2018-04-10 이도르시아 파마슈티컬스 리미티드 Alx 수용체 작용제로서의 히드록실화 아미노트리아졸 유도체
CA2816376C (en) 2010-12-07 2018-11-20 Actelion Pharmaceuticals Ltd Oxazolyl-methylether derivatives as alx receptor agonists
CA2841983A1 (en) 2011-07-11 2013-01-17 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
WO2013171687A1 (en) 2012-05-16 2013-11-21 Actelion Pharmaceuticals Ltd 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
CA2899804A1 (en) 2013-03-06 2014-09-12 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
RU2663911C2 (ru) 2013-03-06 2018-08-13 Аллерган, Инк. Применение агонистов формилпептидного рецептора 2 для лечения воспалительных заболеваний глаз

Also Published As

Publication number Publication date
MA37618A1 (fr) 2016-12-30
US20150118258A1 (en) 2015-04-30
MA37618B1 (fr) 2017-08-31
EP2850060B1 (en) 2016-07-13
AU2013261091B2 (en) 2017-04-06
US9139524B2 (en) 2015-09-22
AR091059A1 (es) 2014-12-30
TW201348198A (zh) 2013-12-01
MX2014013829A (es) 2015-02-04
CL2014002918A1 (es) 2015-02-06
TWI579269B (zh) 2017-04-21
WO2013171694A1 (en) 2013-11-21
NZ702971A (en) 2016-09-30
KR20150013285A (ko) 2015-02-04
SG11201406971WA (en) 2014-11-27
CN104321309A (zh) 2015-01-28
BR112014028358A2 (pt) 2020-07-21
CA2871336A1 (en) 2013-11-21
ZA201409249B (en) 2016-09-28
IL235660A0 (en) 2015-02-01
ES2595219T3 (es) 2016-12-28
PH12014502465A1 (en) 2014-12-22
CN104321309B (zh) 2016-06-22
EP2850060A1 (en) 2015-03-25
JP6101789B2 (ja) 2017-03-22
HK1208441A1 (en) 2016-03-04
EA025264B1 (ru) 2016-12-30
PL2850060T3 (pl) 2017-01-31
MX355221B (es) 2018-04-10
AU2013261091A1 (en) 2015-01-22
JP2015516463A (ja) 2015-06-11

Similar Documents

Publication Publication Date Title
PH12014502465A1 (en) Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201390576A1 (ru) Противовирусные соединения
EA201590873A1 (ru) Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201790781A3 (ru) Противовирусные соединения
EA201490037A1 (ru) Антагонисты trpv4
EA201790963A1 (ru) Противовирусные соединения
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
MX2016001788A (es) Derivados de benzimidazolil-metil urea como agonistas del receptor de alx.
EA201600366A1 (ru) Производные бензимидазол-пролина
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
EA201500628A1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201370018A1 (ru) Составы рифаксимина и их применение
EA201391662A1 (ru) Соединения с активностью антагонистов мускариновых рецепторов и агонистов адренергического рецептора бета2
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
EA201590562A1 (ru) Бензамиды
WO2012066488A3 (en) Bridged spiro[2.4]heptane ester derivatives

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU